Back to ALNY
Approved
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
1 competitor in hATTR Amyloidosis
View Full LandscapeDrug Information
Target Indication
hATTR Amyloidosis
Mechanism of Action
RNAi Therapeutic
Clinical Trial
NCT03759379Last updated: 12/3/2025
Patent & Exclusivity
ActiveRLD
Latest Patent Expiry
Jul 28, 2036(9y 11m)
Patents Listed
13
Exclusivity
I-964NCEODE-212ODE-527
Application
NDA 215515Regulatory Approvals
EMA9/15/2022
Amvuttra
Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts